Cervical mucus can be used for metabolite screening in cervical cancer

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancer Science Pub Date : 2024-08-22 DOI:10.1111/cas.16323
Rie Kawasaki, Iwao Kukimoto, Tetsuya Tsukamoto, Eiji Nishio, Aya Iwata, Takuma Fujii
{"title":"Cervical mucus can be used for metabolite screening in cervical cancer","authors":"Rie Kawasaki,&nbsp;Iwao Kukimoto,&nbsp;Tetsuya Tsukamoto,&nbsp;Eiji Nishio,&nbsp;Aya Iwata,&nbsp;Takuma Fujii","doi":"10.1111/cas.16323","DOIUrl":null,"url":null,"abstract":"<p>Approximately 660,000 women are diagnosed with cervical cancer annually. Current screening options such as cytology or human papillomavirus testing have limitations, creating a need to identify more effective ancillary biomarkers for triage. Here, we evaluated whether metabolomic analysis of cervical mucus metabolism could be used to identify biomarkers of cervical intraepithelial neoplasia (CIN) and cervical cancer. The case–control group consisted of 181 CIN, 69 squamous cell carcinoma (SCC) patients, and 48 healthy controls in the primary cohort. We undertook metabolomic analyses using ultra-HPLC–tandem mass spectrometry. Univariate and multivariate analyses were carried out to profile metabolite characteristics, and receiver operating characteristic (ROC) analysis identified biomarker candidates. Five metabolites conferred the highest discriminatory power for SCC: oxidized glutathione (GSSG) (area under the ROC curve, 0.924; 95% confidence interval, 0.877–0.971), malic acid (0.914, 0.859–0.968), kynurenine (0.884, 0.823–0.945), GSSG/glutathione (GSH) (0.936, 0.892–0.979), and kynurenine/tryptophan (0.909, 0.856–0.961). Malic acid was the best marker for detection of CIN2 or worse (0.858, 0.793–0.922) and was a clinically useful metabolite. We confirmed the reproducibility of the results by validation cohort. Additionally, metabolomic analyses revealed eight pathways strongly associated with cervical neoplasia. Of these, only the tricarboxylic acid cycle was strongly associated with all CINs and cancer, indicating active energy production. Aberrant arginine metabolism by decreasing arginine and increasing citrulline might reduce tumor immunity. Changes in cysteine-methionine and GSH pathways might drive the initiation and progression of cervical cancer. These results suggest that metabolic analysis can identify ancillary biomarkers and could improve our understanding of the pathophysiological mechanisms underlying cervical neoplasia.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 11","pages":"3672-3681"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531950/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16323","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Approximately 660,000 women are diagnosed with cervical cancer annually. Current screening options such as cytology or human papillomavirus testing have limitations, creating a need to identify more effective ancillary biomarkers for triage. Here, we evaluated whether metabolomic analysis of cervical mucus metabolism could be used to identify biomarkers of cervical intraepithelial neoplasia (CIN) and cervical cancer. The case–control group consisted of 181 CIN, 69 squamous cell carcinoma (SCC) patients, and 48 healthy controls in the primary cohort. We undertook metabolomic analyses using ultra-HPLC–tandem mass spectrometry. Univariate and multivariate analyses were carried out to profile metabolite characteristics, and receiver operating characteristic (ROC) analysis identified biomarker candidates. Five metabolites conferred the highest discriminatory power for SCC: oxidized glutathione (GSSG) (area under the ROC curve, 0.924; 95% confidence interval, 0.877–0.971), malic acid (0.914, 0.859–0.968), kynurenine (0.884, 0.823–0.945), GSSG/glutathione (GSH) (0.936, 0.892–0.979), and kynurenine/tryptophan (0.909, 0.856–0.961). Malic acid was the best marker for detection of CIN2 or worse (0.858, 0.793–0.922) and was a clinically useful metabolite. We confirmed the reproducibility of the results by validation cohort. Additionally, metabolomic analyses revealed eight pathways strongly associated with cervical neoplasia. Of these, only the tricarboxylic acid cycle was strongly associated with all CINs and cancer, indicating active energy production. Aberrant arginine metabolism by decreasing arginine and increasing citrulline might reduce tumor immunity. Changes in cysteine-methionine and GSH pathways might drive the initiation and progression of cervical cancer. These results suggest that metabolic analysis can identify ancillary biomarkers and could improve our understanding of the pathophysiological mechanisms underlying cervical neoplasia.

Abstract Image

Abstract Image

宫颈粘液可用于宫颈癌代谢物筛查。
每年约有 66 万名妇女被诊断出患有宫颈癌。目前的筛查方法(如细胞学或人类乳头瘤病毒检测)有其局限性,因此需要找出更有效的辅助生物标志物来进行分诊。在此,我们评估了宫颈粘液代谢的代谢组学分析是否可用于确定宫颈上皮内瘤变(CIN)和宫颈癌的生物标志物。病例对照组由 181 名 CIN 患者、69 名鳞状细胞癌 (SCC) 患者和 48 名健康对照者组成。我们采用超高效液相色谱-串联质谱法进行了代谢组学分析。我们对代谢物的特征进行了单变量和多变量分析,并通过接收器操作特征(ROC)分析确定了候选生物标记物。五种代谢物对 SCC 的鉴别力最高:氧化谷胱甘肽(GSSG)(ROC 曲线下面积为 0.924;95% 置信区间为 0.877-0.971)、苹果酸(0.914,0.859-0.968)、犬尿氨酸(0.884,0.823-0.945)、GSSG/谷胱甘肽(GSH)(0.936,0.892-0.979)和犬尿氨酸/色氨酸(0.909,0.856-0.961)。苹果酸是检测 CIN2 或更差的最佳标记物(0.858,0.793-0.922),也是临床上有用的代谢物。我们通过验证队列确认了结果的可重复性。此外,代谢组学分析还揭示了与宫颈肿瘤密切相关的八条通路。其中,只有三羧酸循环与所有 CIN 和癌症密切相关,表明能量产生活跃。精氨酸代谢异常导致精氨酸减少而瓜氨酸增加,可能会降低肿瘤免疫力。半胱氨酸-蛋氨酸和 GSH 途径的变化可能会导致宫颈癌的发生和发展。这些结果表明,代谢分析可以确定辅助生物标志物,并能提高我们对宫颈肿瘤的病理生理机制的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Science
Cancer Science 医学-肿瘤学
自引率
3.50%
发文量
406
审稿时长
2 months
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信